Drug Trial Radar · NCT03662659
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
274
Actual
Start
Oct 16, 2018
Primary completion
Aug 27, 2020
Study completion Jan 18, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.
Conditions
- Gastric Cancer
- Cancer of the Stomach
- Esophagogastric Junction
Interventions
BMS-986213Biological
Relatlimab + Nivolumab specified dose on specified days
NivolumabBiological
Specified dose on specified days
XELOXDrug
Oxaliplatin + capecitabine
FOLFOXDrug
Oxaliplatin + leucovorin + fluorouracil
SOXDrug
Oxaliplatin + tegafur/gimeracil/oteracil potassium
Primary outcomes
What the sponsor says the trial is designed to measure.
- BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) ParticipantsTime frame: Up to 25 months
- BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants - Extended CollectionTime frame: From randomization date to the date of objectively documented progression, death due to any cause, or date of subsequent anticancer therapy, whichever occurs first (Up to 63 months)
Locations
79 sites in 17 countries. Site status is shown where the registry gives one.
Local Institution - 0049
Clovis, California
Local Institution - 0064
Duarte, California
Scripps Clinic
La Jolla, California
Local Institution - 0040
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Local Institution - 0041
Orange, California
Local Institution - 0077
Santa Monica, California
Local Institution - 0056
Aurora, Colorado
Local Institution - 0062
New Haven, Connecticut
Local Institution - 0050
Hackensack, New Jersey
Local Institution - 0054
Dallas, Texas
Virginia Cancer Institute
Richmond, Virginia
Local Institution - 0052
Seattle, Washington
Local Institution - 0078
CABA, Argentina
Local Institution - 0010
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0009
Buenos Aires, Buenos Aires F.D., Argentina
Local Institution - 0011
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0028
Bedford Park, Australia
Local Institution - 0027
Westmead, New South Wales, Australia
Local Institution - 0007
Herston, Queensland, Australia
Local Institution - 0003
Heidelberg, Victoria, Australia
Local Institution - 0029
Malvern, Victoria, Australia
Local Institution - 0008
Shepparton, Victoria, Australia
Local Institution - 0005
Murdoch, Western Australia, Australia
Local Institution - 0090
Graz, Austria
Local Institution - 0089
Vienna, Austria
Local Institution - 0091
Brussels, Belgium
Local Institution - 0092
Leuven, Belgium
Local Institution - 0024
Kelowna, British Columbia, Canada
Local Institution - 0063
Halifax, Nova Scotia, Canada
Local Institution - 0070
Toronto, Ontario, Canada
Local Institution - 0095
Québec, Quebec, Canada
Local Institution - 0055
Trois-Rivières, Quebec, Canada
Local Institution - 0079
Santiago, Chile
Local Institution - 0002
Rancagua, L.g.bernardoohiggins, Chile
Local Institution - 0080
Santiago, Santiago Metropolitan, Chile
Local Institution - 0001
Viña del Mar, Valparaiso, Chile
Local Institution - 0031
Brno, Czechia
Local Institution - 0030
Olomouc, Czechia
Local Institution - 0047
Avignon, France
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.